A public pharmaceutical platform company

Vicapsys Life Sciences, Inc. (OTC: VICP) is headquartered in Miami, Florida, with operations in San Juan, Puerto Rico. On September 3, 2026 it completed its merger with Stateline Distributors of Puerto Rico, Inc., a licensed wholesale drug distributor, which is now a wholly owned subsidiary.

Who we are

The company serves the markets the national wholesalers have never prioritized: rural, tribal, Indian Health Service, Veterans Affairs, Department of Defense and Puerto Rico. It does so by combining three things under one public company: licensed wholesale distribution, federal contracting access through a tribal 8(a) teaming partner and owned FDA-approved products.

Stateline is the operating base every other part plugs into. It holds the Puerto Rico wholesale drug distributor and specialty biologics licenses, serves more than 400 active healthcare accounts on the island and, through its title-model agreement with Drugzone Pharmaceuticals and venture alliances with other large-scale distributors, has access to more than 15,000 pharmaceutical SKUs across all 50 states.

Legal name: Vicapsys Life Sciences, Inc.
Trading symbol: VICP (OTC Markets)
Headquarters: Miami, Florida
Operations: San Juan, Puerto Rico
Operating subsidiary: Stateline Distributors of Puerto Rico, Inc. (wholly owned since September 3, 2026)
Legacy program: VICAPSYN^™, held directly by the parent company

The company we are building

Products we own, delivered through licenses we hold, into channels where we have a contracting advantage.

Own

A portfolio of acquired, FDA-approved brands that larger companies have set aside, relaunched through channels we control, with no new clinical risk.

Deliver

Licensed distribution in Puerto Rico and all 50 states, brand supply at DACO pricing, one DSCSA chain of custody to the point of care.

Contract

A recurring book of federal and tribal awards at IHS, VA and DoD for products for which Vicapsys is the only approved source.

2026 so far, and what comes next

Targets are management estimates and depend on closings, FDA review and financing.

Completed in 2026

Date	Milestone
2026	Title-model agreement with Drugzone Pharmaceuticals, Inc., licensed in all 50 states and NABP-accredited: 50-state reach for Stateline
August 12, 2026	Merger agreement with Stateline Distributors of Puerto Rico, Inc. executed
September 3, 2026	Merger closed; Stateline becomes a wholly owned subsidiary
September 2026	Definitive purchase agreement for NitroMist^® (NDA 021780) executed
September 22 and 25, 2026	Merger, NitroMist agreement and eight-member Advisory Board announced
September 23, 2026	OTC Markets disclosure application filed; Form 211 (Rule 15c2-11) in process alongside the PCAOB audit
September 2026	Puerto Rico brand-oncology procurement program initiated at DACO pricing
October 5, 2026	New corporate identity by FutureBrand adopted for Vicapsys and Stateline

Period	Milestone
Q4 2026	Close NitroMist on FDA acknowledgment of the NDA transfer
Q4 2026	OTC Markets disclosure posted; quotation after FINRA clearance
2027	NitroMist commercial relaunch; federal channel opens
2027	PCAOB audit completion (to be announced); SEC reporting; Nasdaq uplisting when eligible

Leadership

Board of Directors: Armando Rubio (Chairman) and Jean Dominguez.

Armando Rubio

Chief Executive Officer and Chairman, Vicapsys; Chairman, Stateline

Serial entrepreneur. Leads the company's macro-infrastructure expansion, contract negotiations, vertical integration into larger distribution and manufacturing contracts through venture alliances, and M&A. Most recently structured the tokenization of more than US$500 million in asset-backed transactions with Unicoin, an SEC-reporting company.

Jean Dominguez

President and Director, Vicapsys; co-founder and Chief Executive Officer / Chief Operating Officer, Stateline

Alberto Dominguez

Chief Financial Officer, Vicapsys; co-founder and President, Stateline

David Wayne Dunn

Executive Vice President of Sales

Humberto Borque

Director of Economic Development, NitroMist

Directed NitroMist under prior ownership, when the product reached peak sales of about US$40 million a year; now leads the relaunch.

Prakash Pathare

Executive Sales Director, Stateline

Angel L. Meléndez Díaz

Pharmacist-in-Charge (Farmacéutico Regente), Stateline

Federico Pier

Lead, VICAPSYN^™ program; former Chief Executive Officer of Vicapsys

Advisory Board

Announced September 25, 2026. Members advise management on strategy, operations and market access; they are advisors, not members of the Board of Directors.

Moe Vela

Two-time White House senior advisor

Federal channels, including the Indian Health Service.

Dr. Makarand (Mak) Jadawakar

Former Pfizer scientist, nearly three decades at the company

Pharmaceutical development, manufacturing and quality, including the NitroMist relaunch.

Dr. Ismael Torres

Former head of oncology for Puerto Rico

Oncology and specialty pharmaceutical supply in Puerto Rico.

Mariano Dall'Orso

Former Global Senior Vice President, Western Union

International financial operations and Latin American markets.

Luis Rey

Managing Partner, FutureBrand Latin America

Brand strategy and corporate identity.

Gustavo Koniszczer